Vanguard discloses zero holding in Medtronic (NYSE: MDT) — Amendment No.10
Rhea-AI Filing Summary
The Vanguard Group filed Amendment No. 10 to a Schedule 13G/A regarding Medtronic PLC common stock, reporting 0 shares beneficially owned and 0% of the class. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries or divisions to report holdings separately.
The statement is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Positive
- None.
Negative
- None.
Insights
Vanguard reports no beneficial stake in Medtronic after internal disaggregation.
The filing records 0 shares and 0% ownership, which the text ties to an internal realignment on January 12, 2026. That release-based disaggregation means reported holdings moved to separate Vanguard entities rather than reflecting an outright sale.
Implications depend on subsidiary reports; subsequent Schedule 13 filings by the disaggregated entities will show where holdings reside.
Amendment follows SEC guidance for disaggregated reporting under Release No. 34-39538.
The filing cites SEC Release No. 34-39538 and states that certain subsidiaries now report separately. This is a compliance-driven disclosure explaining reporting responsibility rather than a change in investment strategy according to the text.
Review the separate filings from the named subsidiaries for precise holdings and voting power details.
FAQ
What does Vanguard report for Medtronic (MDT) in this amendment?
Why does the filing mention January 12, 2026 and SEC Release No. 34-39538?
Who signed the Schedule 13G/A amendment for Vanguard?
Does this amendment indicate Vanguard sold Medtronic shares?